Eplerenone reduced lesion size in early but not advanced atherosclerosis in apolipoprotein E-deficient mice

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 6, 2012, Pages 508-512

  Raz Pasteur, Ayelet ^a,b   Gamliel Lazarovich, Aviva ^b   Coleman, Raymond ^b   Keidar, Shlomo ^a,b  

^a RAMBAM MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

advanced atherosclerosis; eplerenone; inflammation; macrophage polarization; mineralocorticoid receptor blocker

Indexed keywords

APOLIPOPROTEIN E; ARGINASE 1; EPLERENONE; INTERLEUKIN 6; MESSENGER RNA; MINERALOCORTICOID ANTAGONIST; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; HISTOPATHOLOGY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK REDUCTION; TREATMENT DURATION;

ALDOSTERONE SYNTHASE; ANIMALS; AORTA, THORACIC; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; INFLAMMATION MEDIATORS; LIPIDS; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, KNOCKOUT; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, MINERALOCORTICOID; RNA, MESSENGER; SPIRONOLACTONE;

EID: 84871530951     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31826f5535     Document Type: Article

References (26)

1. Mendis S, Puska P, Norrving B, eds. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva: World Health Organization; 2011.
2. Rocha R, Stier CT Jr. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab. 2001;12:308-314.
3. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312-318.
4. Rocha R, Funder JW. The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci. 2002;970:89-100.
5. Stowasser M, Sharman J, Leano R, et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90:5070-5076.
6. Milliez P, Girerd X, Plouin PF, et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243-1248.
7. Keidar S, Kaplan M, Pavlotzky E, et al. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004; 109:2213-2220.
8. Pitt B. Effect of aldosterone blockade in patients with systolic left ventricular dysfunction: implications of the RALES and EPHESUS studies. Mol Cell Endocrinol. 2004;217:53-58.
9. De Gasparo M, Joss U, Ramjoué HP, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656.
10. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol. 2003;41:955-963.
11. Rajagopalan S, Duquaine D, King S, et al. Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation. 2002;105:2212-2216.
12. Takai S, Jin D, Muramatsu M, et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 2005;46:1135-1139.
13. Bendtzen K, Hansen PR, Rieneck K; Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol. 2003;134:151-158.
14. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett. 2004;91:87-91.
15. Coleman R, Hayek T, Keidar S, et al. A mouse model for human atherosclerosis: long term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient mice. Acta Histochem. 2006; 108:415-424.
16. Suzuki J, Iwai M, Mogi M, et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol. 2006;26:917-921.
17. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008; 51:161-167.
18. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341-355.
19. Ley K, Miller YI, Hedrick CC. Monocyte and macrophage dynamics during atherogenesis. Arterioscler Thromb Vasc Biol. 2011;31:1506-1516.
20. Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone aorta. Front Physiol. 2012;3:44.
21. Blessing E, Preusch M, Kranzhöfer R, et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199:295-303.
22. Rosenfeld ME, Averill MM, Bennett BJ, et al. Progression and disruption of advanced atherosclerotic plaques in murine models. Curr Drug Targets. 2008;9:210-216.
23. Khallou-Laschet J, Varthaman A, Fornasa G, et al. Macrophage plasticity in experimental ATS. PLoS One. 2010;5:e8852.
24. Usher MG, Duan SZ, Ivaschenko CY, et al. Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest. 2010;120:3350-3364.
25. Patchev VK, Brady LS, Karl M, et al. Regulation of HSP90 and corticosteroid receptor mRNA by corticosterone levels in vivo. Mol Cell Endocrinol. 1994;103:57-64.
26. Rickard AJ, Young MJ. Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol. 2009;42:449-459.